Piper Sandler has adjusted its price target for Akoya Biosciences (AKYA, Financial), reducing it from $2.40 to $1.65. This revision comes in response to the firm's assessment of the company's latest quarterly performance.
The decision to lower the target is primarily influenced by Akoya's anticipated decrease in capital expenditures. Despite this adjustment, the firm has maintained a Neutral rating on Akoya's stock, reflecting a balanced outlook on its future performance. Investors will be watching closely to see how Akoya adapts to these expenditure changes and their impact on overall business growth.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Akoya Biosciences Inc (AKYA, Financial) is $2.99 with a high estimate of $5.00 and a low estimate of $1.65. The average target implies an upside of 141.13% from the current price of $1.24. More detailed estimate data can be found on the Akoya Biosciences Inc (AKYA) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Akoya Biosciences Inc's (AKYA, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Akoya Biosciences Inc (AKYA, Financial) in one year is $5.26, suggesting a upside of 324.19% from the current price of $1.24. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Akoya Biosciences Inc (AKYA) Summary page.
